铁木制药
IRWD
3.50
-0.27
-7.16%
铁木制药
US · IRWD
#3609 按市值排名
3.50
-0.27
-7.16%
实时 - 追踪5344个代码 - 心跳于271秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 机构持股总比例下降了1.2个百分点。
机构持股
- 机构持股比例
- 99.00% -1.17pp
- 机构数量
- 260
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund58.67%
Hedge Fund29.20%
Public Company8.71%
Individual/Insider3.24%
Private Company0.83%
Government Pension Fund0.74%
Bank/Investment Bank0.31%
Family Office/Trust0.23%
Insurance Company0.19%
主要股东 截至 2026-06-30
BlackRock
10.77% · 17.79M 股
Armistice Capital LLC
8.43% · 13.93M 股
Sarissa Capital Management LP
5.56% · 9.19M 股
State Street Global Advisors
5.33% · 8.81M 股
Bank of America Corporation
5.26% · 8.68M 股
Renaissance Technologies Corp.
4.84% · 7.99M 股
Vanguard Capital Management, LLC
4.63% · 7.65M 股
AQR Capital Management
3.81% · 6.29M 股
Acadian Asset Management LLC
3.54% · 5.85M 股
Vanguard Portfolio Management, LLC
3.34% · 5.51M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 29次买入 · 21次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Thomas McCourt | Chief Executive Officer | 1.04% |
| Mark Currie | Director | 0.41% |
| Michael Shetzline | Chief Medical Officer, Senior VP and Head of Research & Drug Development | 0.23% |
| Alexander Denner | Independent Director | 0.20% |
| Jon Duane | Independent Director | 0.15% |
| Julie McHugh | Executive Chairperson | 0.15% |
| Tammi Gaskins | Senior Vice President & Chief Commercial Officer. | 0.14% |
| Jay Shepard | Director | 0.14% |
| Marla Kessler | Independent Director | 0.14% |
| John Minardo | Chief Legal Officer | 0.14% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-23 | Michael Shetzline | Chief Medical Officer, Senior VP and Head of Research & Drug Development | Intent to Sell (Form 144) | -83,306 | $4.53 |
| 2026-09-14 | Alexander Denner | Independent Director | Other Acquisition | +3,694 | -- |
| 2026-07-19 | Jeffrey Silber | Chief Medical Officer, Head of Research & Drug Development | Other Acquisition | +137,036 | -- |
| 2026-07-06 | Ronald Silver | Corporate Controller & Principal Accounting Officer | Automatic Disposition | -127,890 | $4.52 |
| 2026-06-15 | Jay Shepard | Director | Other Acquisition | +63,481 | -- |
| 2026-06-15 | Alexander Denner | Independent Director | Other Acquisition | +67,546 | -- |
| 2026-06-15 | Mark Currie | Director | Other Acquisition | +63,481 | -- |
| 2026-06-15 | Catherine Moukheibir | Independent Director | Other Acquisition | +63,481 | -- |
| 2026-06-15 | Julie McHugh | Executive Chairperson | Other Acquisition | +63,481 | -- |
| 2026-06-15 | Julie McHugh | Executive Chairperson | Automatic Disposition | -21,571 | $3.73 |
| 2026-06-15 | Marla Kessler | Independent Director | Other Acquisition | +63,481 | -- |
| 2026-06-15 | Jon Duane | Independent Director | Other Acquisition | +63,481 | -- |
| 2026-05-18 | Ronald Silver | Corporate Controller & Principal Accounting Officer | Other Acquisition | +25,000 | -- |
| 2026-03-16 | Sarissa Capital Management LP | -- | Open Market Disposition | -6,730,800 | $3.05–3.31 |
| 2026-03-12 | Alexander Denner | Independent Director | Other Acquisition | +4,451 | -- |
| 2026-03-09 | Thomas McCourt | Chief Executive Officer | Other Acquisition | +409,836 | -- |
| 2026-03-09 | Michael Shetzline | Chief Medical Officer, Senior VP and Head of Research & Drug Development | Other Acquisition | +136,612 | -- |
| 2026-03-09 | Ronald Silver | Corporate Controller & Principal Accounting Officer | Other Acquisition | +163,934 | -- |
| 2026-03-09 | John Minardo | Chief Legal Officer | Other Acquisition | +136,612 | -- |
| 2026-03-09 | Gregory Martini | Vice President of Strategic Finance & Investor Relations | Other Acquisition | +136,612 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
铁木制药 讨论区 0 条评论